|
1
|
Heinemann V: Gemcitabine: Progress in the
treatment of pancreatic cancer. Oncology. 60:8–18. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Burris HA III, Moore MJ, Andersen J, Green
MR, Rothenberg Ml, Modiano MR, Cripps MC, Portenoy RK, Storniolo
AM, Tarassoff P, et al: Improvements in survival and clinical
benefit with gemcitabine as first-line therapy for patients with
advanced pancreas cancer: A randomized trial. J Clin Oncol.
15:2403–2413. 1997.PubMed/NCBI
|
|
3
|
Carmichael J, Fink U, Russell RC, Spittle
MF, Harris AL, Spiessi G and Blatter J: Phase II study of
gemcitabine in patients with advanced pancreatic cancer. Br J
Cancer. 73:101–105. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Crinò L, Mosconi AM, Calandri C, Corgna E,
Porrozzi S, Chiara S, Nobili MT and Tonato M: Gemcitabine in
advanced pancreatic cancer: A phase II trial. Am J Clin Oncol.
24:296–298. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rocha Lima CM, Savarese D, Bruckner H,
Dudek A, Eckardt J, Hainsworth J, Yunus F, Lester E, Miller W,
Saville W, et al: Irinotecan plus gemcitabine induces both
radiographic and CA 19-9 tumor marker responses in patients with
previously untreated advanced pancreatic cancer. J Clin Oncol.
20:1182–1191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Stathopoulos GP, Mavroudis D, Tsavaris N,
Kouroussis C, Aravantinos G, Agelaki S, Kakolyris S, Rigatos SK,
Karabekios S and Georgoulias V: Treatment of pancreatic cancer with
a combination of docetaxel, gemcitabine and granulocyte
colony-stimulating factor: A phase II study of the Greek
Cooperative Group for Pancreatic Cancer. Ann Oncol. 12:101–103.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shepard RC, Levy DE, Berlin JD, Stuart K,
Harris JE, Aviles V, Thomas JP and Benson AB III: Phase II Study of
gemcitabine in combination with docetaxel in patients with advanced
pancreatic carcinoma (E1298). A trial of the eastern cooperative
oncology group. Oncology. 66:303–309. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Oettle H, Arning M, Pelzer U, Arnold D,
Stroszczynski C, Langrehr J, Reitzig P, Kindler M, Herrenberger J,
Musch R, et al: A phase II trial of gemcitabine in combination with
5-fluorouracil (24-hour) and folinic acid in patients with
chemonaive advanced pancreatic cancer. Ann Oncol. 11:1267–1272.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hidalgo M, Castellano D, Paz-Ares L,
Gravalos C, Diaz-Puente M, Hitt R, Alonso S and Cortes-Funes H:
Phase I-II study of gemcitabine and fluorouracil as a continuous
infusion in patients with pancreatic cancer. J Clin Oncol.
17:585–592. 1999.PubMed/NCBI
|
|
10
|
Berlin JD, Catalano P, Thomas JP, Kugler
JW, Haller DG and Benson AB III: Phase III Study of gemcitabine in
combination with fluorouracil versus gemcitabine alone in patients
with advanced pancreatic carcinoma: Eastern Cooperative Oncology
Group Trial E2297. J Clin Oncol. 20:3270–3275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wils JA, Kok T, Wagener DJT, Selleslags J
and Duez N: Activity of cisplatin in adenocarcinoma of the
pancreas. Eur J Cancer. 29A:203–204. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Heinemann V, Wilke H, Mergenthaler HG,
Clemens M, König H, Illiger HJ, Arning M, Schalhorn A, Possinger K
and Fink U: Gemcitabine and cisplatin in the treatment of advanced
or metastatic pancreatic cancer. Ann Oncol. 11:1399–1403. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Colucci G, Giuliani F, Gebbia V, Biglietto
M, Rabitti P, Uomo G, Cigolari S, Testa A, Maiello E and Lopez M:
Gemcitabine alone or with cisplatin for the treatment of patients
with locally advanced and/or metastatic pancreatic carcinoma: A
prospective, randomized phase III study of the Gruppo Oncologia
dell'Italia Meridionale. Cancer. 94:902–910. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Philip PA, Zalupski MM, Vaitkevicius VK,
Arlauskas P, Chaplen R, Heilbrun LK, Adsay V, Weaver D and Shields
AF: Phase II study of gemcitabine and cisplatin in the treatment of
patients with advanced pancreatic carcinoma. Cancer. 92:569–577.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bruckner HW, Zhou G, Haenel P, Szrajer L,
Greenspan E and Kurbacher C: Ex vivo ATP tumor testing of
gemcitabine for combination chemotherapy and biochemical
modulation. Proc Am Assoc Cancer Res. 39:310a(abstract 2116).
1998.
|
|
16
|
Bergman AM, Ruiz van Haperen VW, Veerman
G, Kuiper CM and Peters GJ: Synergistic interaction between
cisplatin and gemcitabine in vitro. Clin Cancer Res. 2:521–530.
1996.PubMed/NCBI
|
|
17
|
Peters GJ, Ruiz van Haperen VW, Bergman
AM, Veerman G, Smitskamp-Wilms E, van Moorsel CJ, Kuiper CM and
Braakhuis BJ: Preclinical combination therapy with gemcitabine and
mechanisms of resistance. Semin Oncol. 23:(Suppl 10). 16–24.
1996.PubMed/NCBI
|
|
18
|
Peters GJ, Bergman AM, Ruiz van Haperen
VW, Veerman G, Kuiper CM and Braakhuis BJ: Interaction between
cisplatin and gemcitabine in vitro and in vivo. Semin Oncol.
22:(Suppl 11). 72–79. 1995.PubMed/NCBI
|
|
19
|
Peters GJ, Bergman AM, Veerman G and Ruiz
van Haperen VWT: Synergism between cisplatin and gemcitabine (dFdC)
in resistant A2780 human ovarian cancer cell lines is schedule
dependent. Proc Am Assoc Cancer Res. 35:1950(abstract). 1994.
|
|
20
|
Braakhuis BJM, Ruiz van Haperen VWT,
Bergman AM, Welters MJP and Peters GJ: Preclinical in vivo
evaluation of the combination of 2,3 difluorodeoxycytidine (dFdC,
gemcitabine) and cisplatin (CDDP). Ann Oncol. 5:82(abstract 054).
1994.
|
|
21
|
Schabel FM Jr, Trader MW, Laster WR Jr,
Corbett TH and Griswold DP Jr: cis-Dichlorodiammineplatinum(II):
Combination chemotherapy and cross-resistance studies with tumors
of mice. Cancer Treat Rep. 63:1459–1473. 1979.PubMed/NCBI
|
|
22
|
Greene F, Page D, Fleming I, Fritz A,
Balch C, Haller D and Morrow M: AJCC Cancer Staging Manual. 6th.
Springer; New York, NY, USA: pp. 157–161. 2002
|
|
23
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miller AB, Hoogstraten B, Staquet M and
Winkler A: Reporting results of cancer treatment. Cancer.
47:207–214. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fleming TR: One-sample multiple testing
procedure for phase II clinical trials. Biometrics. 38:143–151.
1982. View
Article : Google Scholar : PubMed/NCBI
|
|
26
|
Conroy T, Desseigne F, Ychou M, Bouché O,
Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de
la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for
metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Di Marco M, Di Cicilia R, Macchini M,
Nobili E, Vecchiarelli S, Brandi G and Biasco G: Metastatic
pancreatic cancer: Is gemcitabine still the best standard
treatment? (Review). Oncol Rep. 23:1183–1192. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Herrmann R, Bodoky G, Ruhstaller T,
Glimelius B, Bajetta E, Schüller J, Saletti P, Bauer J, Figer A,
Pestalozzi B, et al: Gemcitabine plus capecitabine compared with
gemcitabine alone in advanced pancreatic cancer: A randomized,
multicenter, phase III trial of the Swiss Group for Clinical Cancer
Research and the Central European Cooperative Oncology Group. J
Clin Oncol. 25:2212–2217. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Heinemann V, Quietzsch D, Gieseler F,
Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M,
Heinrich B, et al: Randomized phase III trial of gemcitabine plus
cisplatin compared with gemcitabine alone in advanced pancreatic
cancer. J Clin Oncol. 24:3946–3952. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Heinemann V, Boeck S, Hinke A, Labianca R
and Louvet C: Meta-analysis of randomized trials: Evaluation of
benefit from gemcitabine-based combination chemotherapy applied in
advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Reni M, Panucci MG, Passoni P, Bonetto E,
Nicoletti R, Ronzoni M, Zerbi A, Staudacher C, Di Carlo V and Villa
E: Salvage chemotherapy with mitomycin, docetaxel, and irinotecan
(MDI Regimen) in metastatic pancreatic adenocarcinoma: A Phase I
and II Trial. Cancer Invest. 22:688–696. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fine R, Moorer G, Sherman W, et al: Phase
II trial of GTX chemotherapy in metastatic pancreatic cancer. J
Clin Oncol. 27:(Suppl 15): abstract. 46232009.
|
|
33
|
Correale P, Montagnani F, Miano S,
Sciandivasci A, Pascucci A, Petrioli R, Testi W, Tanzini G and
Francini G: Biweekly triple combination chemotherapy with
gemcitabine, oxaliplatin, levofolinic acid and 5-fluorouracil
(GOLF) is a safe and active treatment for patients with inoperable
pancreatic cancer. J Chemother. 20:119–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
El-Rayes BF, Zalupski MM, Shields AF,
Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J and Philip PA:
Phase II study of gemcitabine, cisplatin, and infusional
fluorouracil in advanced pancreatic cancer. J Clin Oncol.
21:2920–2925. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Novarino A, Chiappino I, Bertelli GF,
Heouaine A, Ritorto G, Addeo A, Bellone G, Merlano M and Bertetto
O: Phase II study of cisplatin, gemcitabine and 5-fluorouracil in
advanced pancreatic cancer. Ann Oncol. 15:474–477. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Colucci G, Labianca R, Di Costanzo F,
Gebbia V, Cartenì G, Massidda B, Dapretto E, Manzione L, Piazza E,
Sannicolò M, et al: Randomized phase III trial of gemcitabine plus
cisplatin compared with single-agent gemcitabine as first-line
treatment of patients with advanced pancreatic cancer: The GIP-1
study. J Clin Oncol. 28:1645–1651. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Louvet C, André T, Lledo G, Hammel P,
Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E and de
Gramont A: Gemcitabine combined with oxaliplatin in advanced
pancreatic adenocarcinoma: Final results of a GERCOR multicenter
phase II study. J Clin Oncol. 20:1512–1518. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Di Costanzo F, Carlini P, Doni L, Massidda
B, Mattioli R, Iop A, Barletta E, Moscetti L, Recchia F, Tralongo
P, et al: Gemcitabine with or without continuous infusion 5-FU in
advanced pancreatic cancer: A randomised phase II trial of the
Italian oncology group for clinical research (GOIRC). Br J Cancer.
93:185–189. 2005. View Article : Google Scholar : PubMed/NCBI
|
